FAST: Functional Activity Strength Training

Sponsor
Milton S. Hershey Medical Center (Other)
Overall Status
Active, not recruiting
CT.gov ID
NCT05697497
Collaborator
(none)
101
1
4
25.9
3.9

Study Details

Study Description

Brief Summary

This study is a randomized trial of 100 older adults with mobility disability, who performed a similar brief daily, resistance training program. The investigators set out to answer the following question "Will a digital, brief daily exercise program be feasible, acceptable, and effective among older adults with walking limitations?" To answer that question, participants were assigned to an intervention or delayed-treatment control group. Intervention participants were assigned to complete two 30-second lower body exercises and two 30-second upper body exercises. Fitness tests were completed remotely three times during the 12-weeks (i.e., at baseline, week 6, week 12).

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Daily exercise intervention
N/A

Detailed Description

This is a 12-week delayed-control randomized trial to answer the following question "Will a digital, brief daily exercise program be feasible, acceptable, and effective among older adults with walking limitations?" Participants who screen eligible will be assigned to one of four conditions, an immediate workout group, an immediate workout group with activity monitor, a delayed workout group or a delayed workout group with activity monitor. Participants will complete a daily 2.5-to-3.5-minute exercise routine at home and to record their results using an electronic survey. Other outcome measurements will be conducted remotely at baseline, 6, and 12 weeks.

The investigators hypothesize that participants in the AMRAP condition will report significant reductions in functional physical limitations, increased gait speed, and increased physical performance (i.e., increased exercise repetitions) from baseline to 6 weeks compared to those randomized to the delayed-treatment control.

Study Design

Study Type:
Interventional
Actual Enrollment :
101 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
A delayed treatment control group will be used to compare the effects of the intervention to a control group. Both groups will complete their study visits at baseline, week 6, and week 12, with the intervention group starting their exercises immediately after the baseline visit and the delayed treatment control group starting their exercise intervention after their week 12 visit.A delayed treatment control group will be used to compare the effects of the intervention to a control group. Both groups will complete their study visits at baseline, week 6, and week 12, with the intervention group starting their exercises immediately after the baseline visit and the delayed treatment control group starting their exercise intervention after their week 12 visit.
Masking:
Single (Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
A Brief Digital Exercise Program to Improve Physical Function Among Older Adults
Actual Study Start Date :
May 1, 2021
Actual Primary Completion Date :
May 27, 2022
Anticipated Study Completion Date :
Jun 27, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: Immediate start group with gait cadence assessment

This group will wear an activPAL device for 10 days prior to their baseline assessment and for 10 days after their week 12 assessment. The exercise intervention consists of a 2.5 to 3.5 minute daily routine that includes 2 upper body and 2 lower body exercises.

Behavioral: Daily exercise intervention
Participants will complete four exercises each day, The first two weeks they will be instructed to complete as many repetitions as possible, each day, for 15 seconds and progressing to 30 seconds per exercise after the first two weeks. Participants are asked to increase their goal repetitions by 1 or 2 from their previous best each week. For all exercises with modifications, we will encourage participants to move to the next most difficult modification once they can do 15 repetitions of that exercise.

Experimental: Immediate start group without gait cadence assessment

The exercise intervention consists of a 2.5 to 3.5 minute daily routine that includes 2 upper body and 2 lower body exercises.

Behavioral: Daily exercise intervention
Participants will complete four exercises each day, The first two weeks they will be instructed to complete as many repetitions as possible, each day, for 15 seconds and progressing to 30 seconds per exercise after the first two weeks. Participants are asked to increase their goal repetitions by 1 or 2 from their previous best each week. For all exercises with modifications, we will encourage participants to move to the next most difficult modification once they can do 15 repetitions of that exercise.

No Intervention: Delayed-treatment control group with gait cadence assessment

This group will wear an activPAL device for 10 days prior to their baseline assessment and for 10 days after their week 12 assessment. The exercise intervention consists of a 2.5 to 3.5 minute daily routine that includes 2 upper body and 2 lower body exercises. Participants in the this arm will not start the exercise intervention until the day after the week 12 assessment.

No Intervention: Delayed-treatment control group without gait cadence assessment

The exercise intervention consists of a 2.5 to 3.5 minute daily routine that includes 2 upper body and 2 lower body exercises. Participants in the this arm will not start the exercise intervention until the day after the week 12 assessment.

Outcome Measures

Primary Outcome Measures

  1. 30-Second Chair Stand [Baseline]

    Leg strength and endurance test - number of chair stand repetitions in 30 seconds

  2. 30-Second Chair Stand [6 weeks]

    Leg strength and endurance test - number of chair stand repetitions in 30 seconds

  3. 30-Second Chair Stand [12 weeks]

    Leg strength and endurance test - number of chair stand repetitions in 30 seconds

  4. Five Time Sit to Stand Test (5TSTS) [Baseline]

    The Five Times Sit to Stand Test measures one aspect of transfer skill. The test provides a method to quantify functional lower extremity strength and/or identify movement strategies a patient uses to complete transitional movements. The score is the amount of time (to the nearest decimal in seconds) it takes a patient to transfer from a seated to a standing position and back to sitting five times.

  5. Five Time Sit to Stand Test (5TSTS) [6 weeks]

    The Five Times Sit to Stand Test measures one aspect of transfer skill. The test provides a method to quantify functional lower extremity strength and/or identify movement strategies a patient uses to complete transitional movements. The score is the amount of time (to the nearest decimal in seconds) it takes a patient to transfer from a seated to a standing position and back to sitting five times.

  6. Five Time Sit to Stand Test (5TSTS) [12 weeks]

    The Five Times Sit to Stand Test measures one aspect of transfer skill. The test provides a method to quantify functional lower extremity strength and/or identify movement strategies a patient uses to complete transitional movements. The score is the amount of time (to the nearest decimal in seconds) it takes a patient to transfer from a seated to a standing position and back to sitting five times.

  7. Single Leg Stance Test (SLS) [12 weeks]

    Assessment of static postural and balance control.

  8. Functional limitations [12 weeks]

    Physical Functioning Questionnaire from the National Health and Nutrition Examination Survey

  9. Falls [12 weeks]

    Falls over the past 3 months will be assessed using the Behavioral Risk Factor Surveillance System survey.

Secondary Outcome Measures

  1. Walking gait cadence [10 day period pre and post intervention]

    Gait cadence will be measured in 50% of the participants using an activPAL device.

  2. Pain on the Patient Reported Outcomes Measurement Information System (PROMIS) survey [12 weeks]

    Survey using questions from the NIH-supported Patient Reported Outcomes Measurement Information System (PROMIS). The minimal value for pain interference is not at all, while the minimum value for pain intensity is no pain. The maximum value for pain interference is very much, while the maximum value for pain intensity is worst pain imaginable. A higher score generally means a worse outcome.

  3. Fatigue on the Patient Reported Outcomes Measurement Information System (PROMIS) survey [12 weeks]

    Survey using questions from the NIH-supported Patient Reported Outcomes Measurement Information System (PROMIS). The minimum value for fatigue is not at all, while the maximum value is very much. A higher score generally means a worse outcome.

  4. Self-Efficay for Physical Activity (SEPA) [12 weeks]

    5-item measure that assesses an individual's confidence for engaging in exercise in the presence of barriers.

  5. Percent of sessions attended [12 weeks]

    Patients will be considered adherent to the intervention when they enter their daily exercise performance data via daily survey. The percent of sessions attended will be calculated by dividing the number of sessions attended by the total number of sessions offered and multiplying the result by 100.

  6. Heart rate [12 weeks]

    resting and maximal heart rates will be collected during the maximal exercise performance tests

Eligibility Criteria

Criteria

Ages Eligible for Study:
65 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Age 65 and older

  • Difficulty with walking

  • Providers must provide consent for their patient

  • Access to the internet

  • Must have a camera on computer, tablet, or smartphone

  • Fluent in Egnlish

Exclusion Criteria:
  • Chest pain or a heart condition on the PAR-Q

  • Planning to have surgery in the next 3 months

  • Cognitive impairment

  • Unable to exercise

  • Being currently physically active

Contacts and Locations

Locations

Site City State Country Postal Code
1 Penn State Hershey Medical Center Hershey Pennsylvania United States 17033

Sponsors and Collaborators

  • Milton S. Hershey Medical Center

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Christopher Sciamanna, MD, MPH, Professor and Vice Chair for Research Affairs, Department of Medicine, Milton S. Hershey Medical Center
ClinicalTrials.gov Identifier:
NCT05697497
Other Study ID Numbers:
  • STUDY00016054
First Posted:
Jan 26, 2023
Last Update Posted:
Jan 26, 2023
Last Verified:
Jan 1, 2023
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jan 26, 2023